




Searching News Database: metastatic melanoma
HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 2 Sep 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
HSMN NewsFeed - 30 Sep 2013
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed - 18 Jun 2012
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 5 Apr 2012
Delcath Receives European Regulatory Approval for Second Generation Hemofiltration Cartridge
Delcath Receives European Regulatory Approval for Second Generation Hemofiltration Cartridge
HSMN NewsFeed - 19 Mar 2012
Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
HSMN NewsFeed - 13 Feb 2012
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
HSMN NewsFeed - 3 May 2011
Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
HSMN NewsFeed - 13 Apr 2011
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT Delivery System
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT Delivery System
HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
HSMN NewsFeed - 22 Dec 2010
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
HSMN NewsFeed - 6 Dec 2010
Delcath Submits CE Mark Technical File for Hepatic ChemoSAT Delivery System
Delcath Submits CE Mark Technical File for Hepatic ChemoSAT Delivery System
HSMN NewsFeed - 1 Dec 2010
Delcath Names Bernard R. Tyrrell as Senior Vice President for North American Sales and Marketing
Delcath Names Bernard R. Tyrrell as Senior Vice President for North American Sales and Marketing
HSMN NewsFeed - 14 Jul 2010
Douglas G. Watson, Former CEO of Novartis Corporation, Joins Delcath Board of Directors
Douglas G. Watson, Former CEO of Novartis Corporation, Joins Delcath Board of Directors
HSMN NewsFeed - 22 Apr 2010
Delcath Systems Appoints Peter J. Graham as Executive Vice President and General Counsel
Delcath Systems Appoints Peter J. Graham as Executive Vice President and General Counsel
HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
HSMN NewsFeed - 1 Mar 2010
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
HSMN NewsFeed - 21 Oct 2009
Antigenics Announces a Negative Vote From the CHMP on Oncophage(R) Marketing Application in Europe
Antigenics Announces a Negative Vote From the CHMP on Oncophage(R) Marketing Application in Europe
HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
HSMN NewsFeed - 29 Apr 2009
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
HSMN NewsFeed - 18 Nov 2008
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
HSMN NewsFeed - 14 Jul 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 10 Jun 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
HSMN NewsFeed - 3 Jun 2008
Provectus Pharmaceuticals Appoints Kelly M. McMasters, MD, PhD, to Board of Directors
Provectus Pharmaceuticals Appoints Kelly M. McMasters, MD, PhD, to Board of Directors
HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
HSMN NewsFeed - 8 Apr 2008
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed - 28 Jan 2008
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
HSMN NewsFeed - 8 Nov 2007
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
HSMN NewsFeed - 28 Aug 2007
Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
HSMN NewsFeed - 30 May 2007
Delcath Systems Receives National Cancer Institute Approval to Expand Phase III Trial to Multiple Centers
Delcath Systems Receives National Cancer Institute Approval to Expand Phase III Trial to Multiple Centers
HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
HSMN NewsFeed - 12 Apr 2007
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
HSMN NewsFeed - 27 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
HSMN NewsFeed - 24 Jan 2007
Vical Highlights Transition to Phase 3 Trial With Allovectin-7(R) for Metastatic Melanoma
Vical Highlights Transition to Phase 3 Trial With Allovectin-7(R) for Metastatic Melanoma
HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
HSMN NewsFeed - 29 Nov 2006
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
HSMN NewsFeed - 31 Oct 2006
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
HSMN NewsFeed - 7 Aug 2006
Celator Pharmaceuticals Names Dr. Arthur C. Louie as New Chief Medical Officer
Celator Pharmaceuticals Names Dr. Arthur C. Louie as New Chief Medical Officer
HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
HSMN NewsFeed - 13 Jun 2006
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
HSMN NewsFeed - 28 Apr 2006
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
HSMN NewsFeed - 26 Apr 2006
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
HSMN NewsFeed - 30 Mar 2006
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
HSMN NewsFeed - 22 Feb 2006
Delcath Systems Receives Special Protocol Assessment and Agreement from FDA
Delcath Systems Receives Special Protocol Assessment and Agreement from FDA
HSMN NewsFeed - 2 Feb 2006
Analysis of Genasense(R) Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
Analysis of Genasense(R) Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
Additional items found! 108

Members Archive contains
108 additional stories matching:
metastatic melanoma
(Password required)
metastatic melanoma
(Password required)